As noted above, the characteristic increase in IL-6 during COVID-19 inhibits BMPR2 [120], which normally protects against increased TGFβ signaling [119], and upregulated TGFβ1 contributes to hyperglycemia [190]. The gene discussed is BMPR2; the disease is Hyperglycemia.